Privo Technologies Commences First Human Dosing of PRV131 in Pioneering Oral Cancer Treatment Trial Privo Technologies has officially begun dosing its first patient in a groundbreaking clinical trial for PRV131, an innovative injectable for oral cavity cancer, showcasing phase 1/2 advancements.

Privo Technologies Commences First Human Dosing of PRV131 in Pioneering Oral Cancer Treatment Trial #USA #Boston #Privo_Technologies #Oral_Cancer #PRV131